Good Evening Friends and Colleagues,
What are your thought on starting Cabenuva (CAB/RPV) in a patient with a genotyped K103N mutation? I know this mutation can generally confer resistance to NNRTI's especially NVP; however, the patient does not have the L100I mutation, so literature I have reviewed seems to lean towards CAB/RPV should be okay. The patient has no resistance to RPV or CAB. Doing a chart review, it looks like this was an acquired mutation, he had no documented treatment failures, and was diagnosed with a low viral load and started on Dovato as an initial regimen (not by me).
Thank you for your time.
------------------------------
Martel S. Warden, MHA, MSN, APRN
Family Nurse Practitioner
Christian Community Health Center
Chicago, IL 60628
------------------------------